Engineered viruses have great potential as cancer treatments. However, the only currently approved viral therapy, T-vec (Talimogene laherparepvec), suffers from off-target effects that limit its use to intratumoral injection.
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.